Our results suggest that patients with advanced disease and low K17 benefit from 5-FU–based therapies compared with gemcitabine-based chemotherapies, whereas patients with advanced disease with expression of K17 in 10% or more of tumor cells respond poorly to either therapy regimen. This evidence concerns the gene KRT17 and neoplasm.